By Steve Moore | Wednesday 20 October 2021
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
In May I concluded with shares in “the UK’s leading independent tissue converter” Accrol (ACRL) lower at 54p to avoid as inflationary pressures could persist for some time given the wide pandemic response. The shares last closed at 44.95p and are currently below 40p on the back of a trading update…